Jay Garg

4.1k total citations · 2 hit papers
42 papers, 2.6k citations indexed

About

Jay Garg is a scholar working on Rheumatology, Nephrology and Immunology. According to data from OpenAlex, Jay Garg has authored 42 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 15 papers in Nephrology and 14 papers in Immunology. Recurrent topics in Jay Garg's work include Systemic Lupus Erythematosus Research (21 papers), Renal Diseases and Glomerulopathies (10 papers) and T-cell and B-cell Immunology (10 papers). Jay Garg is often cited by papers focused on Systemic Lupus Erythematosus Research (21 papers), Renal Diseases and Glomerulopathies (10 papers) and T-cell and B-cell Immunology (10 papers). Jay Garg collaborates with scholars based in United States, Switzerland and Mexico. Jay Garg's co-authors include George L. Bakris, Paul Brunetta, Brad H. Rovin, Richard Furie, R. John Looney, Fernando C. Fervenza, Gerald B. Appel, Jorge Sánchez‐Guerrero, David Zhang and Romeo Maciuca and has published in prestigious journals such as Circulation, Hypertension and Journal of the American Society of Nephrology.

In The Last Decade

Jay Garg

38 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

2012 972 citations Brad H. Rovin, Richard Furie et al. Arthritis & Rheumatism profile →
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

2022 237 citations Richard Furie, Gustavo Aroca et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Garg United States	15	1.4k	832	652	542	488	42	2.6k
Gabriel Contreras United States	35	2.8k 2.1×	1.2k 1.4×	2.4k 3.6×	660 1.2×	593 1.2×	85	4.9k
Young Hee Rho South Korea	28	1.1k 0.8×	757 0.9×	357 0.5×	152 0.3×	413 0.8×	49	2.5k
Paul R. J. Ames United Kingdom	32	1.4k 1.0×	736 0.9×	116 0.2×	134 0.2×	260 0.5×	124	2.9k
David McCarey United Kingdom	10	1.9k 1.4×	806 1.0×	75 0.1×	99 0.2×	554 1.1×	14	3.1k
Vincenzo Brancaccio Italy	26	1.1k 0.8×	249 0.3×	145 0.2×	92 0.2×	456 0.9×	55	3.6k
Heather N. Reich Canada	43	656 0.5×	849 1.0×	3.8k 5.8×	144 0.3×	896 1.8×	143	5.9k
James V. Donadío United States	34	820 0.6×	479 0.6×	2.5k 3.8×	141 0.3×	122 0.3×	75	4.0k
Christina Charles‐Schoeman United States	30	2.3k 1.7×	889 1.1×	45 0.1×	123 0.2×	353 0.7×	91	3.6k
Sonia Pasquali Italy	26	477 0.4×	315 0.4×	1.7k 2.6×	78 0.1×	166 0.3×	48	2.7k
Daniel Cattran Canada	38	441 0.3×	583 0.7×	4.5k 7.0×	89 0.2×	340 0.7×	84	5.7k

Countries citing papers authored by Jay Garg

Since Specialization

Citations

This map shows the geographic impact of Jay Garg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Garg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Garg more than expected).

Fields of papers citing papers by Jay Garg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Garg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Garg. The network helps show where Jay Garg may publish in the future.

Co-authorship network of co-authors of Jay Garg

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Garg. A scholar is included among the top collaborators of Jay Garg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Garg. Jay Garg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rovin, Brad H., Valeria Albertón, Jay Garg, et al.. (2025). Beyond Clinical Response in the REGENCY Trial: The Impact of Obinutuzumab on Histologic Remission in Patients with Active Lupus Nephritis. Journal of the American Society of Nephrology. 36(10S).

Rovin, Brad H., Richard Furie, Jay Garg, et al.. (2025). WCN25-3676 RESULTS FROM THE REGENCY TRIAL ASSESSING EFFICACY AND SAFETY OF OBINUTUZUMAB IN ACTIVE LUPUS NEPHRITIS. Kidney International Reports. 10(2). S771–S772. 1 indexed citations

Looney, Cary M., Jay Garg, Thomas H. Schindler, et al.. (2023). Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients. Transplantation Direct. 9(2). e1436–e1436. 8 indexed citations

Furie, Richard, Gustavo Aroca, Matthew D. Cascino, et al.. (2022). B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 81(1). 100–107. 237 indexed citations breakdown →

Genovese, Mark C., Maria Greenwald, Sergio Gutiérrez‐Ureña, et al.. (2019). Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. Rheumatology and Therapy. 6(4). 503–520. 12 indexed citations

Garg, Jay, et al.. (2017). SAT0242 Measures of peripheral blood b-cell depletion predict renal response in patients with lupus nephritis treated with rituximab. Annals of the Rheumatic Diseases. 76. 865–865. 1 indexed citations

Zhu, Tong, Barbara A. Parker, Tetsuya Nishimura, et al.. (2016). Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects. Clinical Pharmacokinetics. 56(7). 747–757. 10 indexed citations

Garg, Jay & Domagoj Vucic. (2016). Targeting Cell Death Pathways for Therapeutic Intervention in Kidney Diseases. Seminars in Nephrology. 36(3). 153–161. 25 indexed citations

Kivitz, Alan, Sergio Gutiérrez‐Ureña, Jeffrey E. Poiley, et al.. (2016). Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate. Arthritis & Rheumatology. 69(4). 709–719. 87 indexed citations

10.

Takeuchi, Tsutomu, et al.. (2014). OP0149 A Phase 2B Study of an Oral JAK Inhibitor ASP015K Monotherapy in Japanese Patients with Moderate to Severe Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 73. 117–117. 3 indexed citations

11.

Rovin, Brad H., Richard Furie, Kevin Latinis, et al.. (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis & Rheumatism. 64(4). 1215–1226. 972 indexed citations breakdown →

12.

Pelletier, Elise M., Sarika Ogale, Elaine Yu, Paul Brunetta, & Jay Garg. (2009). Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database. Clinical Therapeutics. 31(11). 2653–2664. 58 indexed citations

13.

Vincenti, Flavio, R. Méndez, Mark D. Pescovitz, et al.. (2007). A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation. American Journal of Transplantation. 7(7). 1770–1777. 116 indexed citations

14.

Zillich, Alan J., Jay Garg, Sanjib Basu, George L. Bakris, & Barry L. Carter. (2006). Thiazide Diuretics, Potassium, and the Development of Diabetes. Hypertension. 48(2). 219–224. 289 indexed citations

15.

Garg, Jay, Andrew T. Blair, Melissa A. Plone, et al.. (2005). Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis & Rheumatism. 52(1). 290–295. 93 indexed citations

16.

Garg, Jay, et al.. (2005). Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts. American Journal of Hypertension. 18(5). 619–626. 189 indexed citations

17.

Garg, Jay, et al.. (2005). Bone disease and bottle caps. Journal of Renal Nutrition. 15(2). 257–259.

18.

Garg, Jay, et al.. (2005). Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology. 25(4). 393–399. 13 indexed citations

19.

Garg, Jay & George L. Bakris. (2002). Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports. 4(3). 185–190. 12 indexed citations

20.

Garg, Jay & George L. Bakris. (2002). Treatment of Hypertension in Patients with Renal Disease. Cardiovascular Drugs and Therapy. 16(6). 503–510. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact